Milestone Pharmaceuticals is trading 5.44% higher at $0.81 in pre-market; no clear catalyst for the October 7 move was identified. - No fresh company announcement explaining the rise was identified. - The latest listed release, dated September 24, reported enrollment of the first Canadian participant in its ReVeRA-301 Phase 3 trial; that update does not establish a reason for this move. - Broader market indicators are mixed and do not clearly explain the rise.